Premium
Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women
Author(s) -
Ahmed Lavina,
Nalwoga Hawa,
Arnes Jarle B.,
Wabinga Henry,
Micklem David R.,
Akslen Lars A.
Publication year - 2015
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12403
Subject(s) - breast cancer , tissue microarray , immunohistochemistry , estrogen receptor , population , cancer , breast carcinoma , angiogenesis , pathology , cancer research , basal (medicine) , axl receptor tyrosine kinase , biology , receptor tyrosine kinase , oncology , medicine , receptor , jak stat signaling pathway , environmental health , insulin
Axl, a receptor tyrosine kinase belonging to the Tyro/Axl/Mer ( TAM ) family, has been shown to be overexpressed in breast cancer with poor outcome. Moreover, Axl was associated with a basal‐like phenotype ( BLP ) in these tumors. Our aim was to investigate Axl expression in breast cancers from an African population since these tumors are known to be aggressive and have a high frequency of the basal‐like phenotype. We studied 170 paraffin‐embedded breast carcinoma cases by tissue microarrays and immunohistochemical methods. In total, 128 tumor cases (75%) had strong Axl expression and 42 cases (25%) had weak or negative staining. Strong expression of Axl was associated with high tumor grade (p < 0.0005), estrogen receptor ( ER ) negativity (p = 0.024), p53 expression (p = 0.004), P‐cadherin positivity (p = 0.017), and basal‐like phenotypic profiles BLP 2 (p = 0.033) and BLP 3 (p = 0.022). In addition, Axl overexpression also showed an association with markers of tumor cell proliferation and tumor angiogenesis. In conclusion, our findings indicate strong expression of Axl in a high proportion of breast cancer cases among African women and associations with markers of aggressive features, indicating poor prognosis. These findings suggest Axl as a potential therapeutic target in this population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom